Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that treating androgenetic alopecia patients with microneedle-delivered GFC containing FGF5s and NMN increased hair density and diameter compared to normal saline.

This article discusses the potential of combining growth factor therapy with LLLT LED therapy for hair regrowth in androgenetic alopecia, but it does not report new clinical results.

This study found that a 0.5-mm microneedle depth was more effective than 0.3 mm for increasing hair density in AGA patients treated with a topical growth factor cocktail.

This retrospective study found that oral finasteride showed efficacy in 73% of androgenic alopecia patients, with better results linked to early and longer treatment duration.

This study identified different non-genetic factors influencing androgenic alopecia in men with varying genetic risk, which may aid in developing more personalized treatments.

In this study, rs6152 was not significantly associated with androgenetic alopecia in the Indonesian population, but familial history and factors like age, gender, hypertension, and BMI were strongly linked to AGA risk.

This paper introduces Concentration Growth Factor (CGF) as a potential treatment for androgenetic alopecia, but reports no clinical findings on its effectiveness in promoting hair growth.

Hair loss linked to higher heart disease risk in both men and women.

This study found that in androgenetic alopecia, reduced stem cell factor production by dermal papilla cells may lead to decreased pigmentation in hair follicles.

This review evaluates dihydrotestosterone's role in androgenic alopecia and proposes a model suggesting that chronic scalp tension and inflammation contribute to hair follicle miniaturization, identifying fibrosis, calcification, and tension as treatment targets.

This study found that combining ablative fractional CO₂ laser therapy with hair growth factors significantly increased hair density in men with androgenetic alopecia compared to using growth factors alone.

This study suggests that crosstalk between Wnt/β-catenin and TGF-β signaling pathways may contribute to the development of androgenetic alopecia.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

This study found that increasing energy fluence, session duration, and using pulsed irradiation significantly enhance hair regrowth in androgenetic alopecia when using low-level laser therapy, while the number of diodes does not affect outcomes.

In this study, researchers identified key transcriptome changes in male androgenetic alopecia hair follicles, suggesting that HIF-1 pathway genes and Wnt pathway inhibitors could be potential therapeutic targets.

This study reports that monthly subcutaneous injections of concentrated growth factors improved hair appearance and density in patients with androgenetic alopecia, with no side effects observed in the follow-up period.

This study found that combining Concentrated Growth Factors with Follicular Unit Extraction significantly improved hair density and terminal hair ratio in men with androgenetic alopecia compared to FUE alone.

In this case report, a 28-year-old male with androgenetic alopecia showed improved hair density and shaft thickness after four monthly sessions of autologous growth factor concentrate injections, with no adverse effects and high patient satisfaction, suggesting the treatment’s promise as a safe and effective option.

This study found that combining PRP with concentrated growth factors was more effective than PRP alone in promoting hair regrowth for patients with androgenetic alopecia.

In this observational study, researchers found a strong association between higher alcohol and smoking indices and increased severity of male androgenetic alopecia.

This study reported significant improvements in hair density and growth ratio in androgenetic alopecia patients receiving concentrated growth factor injections, with benefits sustained for 6 months.

In this study, injections of PRP and MZT products significantly improved hair thickness, density, and count in AGA patients over six months, with variability observed in the extent of improvement between different formulations.

This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.

In this study, researchers reported that both PRP and L-GF injections are effective in enhancing hair density and reducing recovery time post-transplantation in men with androgenetic alopecia, with L-GF showing slightly better but statistically insignificant results.

In this pilot study, treatment with lyophilized platelet derived growth factors showed improvement in women with androgenetic alopecia, suggesting it may be a promising new therapy.

In this study, the vertex type of male pattern baldness was associated with increased cardiovascular risk factors, suggesting it may serve as a marker for cardiovascular evaluation in men.

This study found that in Korean patients, cardiovascular disease-related risk was significantly associated with male sex, moderate to severe androgenetic alopecia, and particularly FV-type alopecia.

This study found that early-onset androgenetic alopecia is associated with higher prevalence of metabolic syndrome, atheroma plaques, and urinary symptoms related to prostate growth compared to controls.

This study reported that paracrine factors, such as IGF-I and SCF, were reduced in balding hair follicles compared to non-balding ones, while inhibitory factors like TGFß-1 were increased, providing insights into the androgen action in hair follicles.

This study found that patients with alopecia areata and androgenetic alopecia showed increased c-kit expression and decreased Ki-67 expression in hair follicle cells compared to controls, suggesting a possible feedback mechanism involving stem cell factor signaling.